Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsing multiple sclerosis,~* Two relapses in prior 2 years or one relapse in prior year.~Exclusion Criteria:~* Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease,~* Significantly impaired bone marrow function or, significant anemia, leukopenia or thrombocytopenia,~* Pregnant or nursing woman,~* Alcohol or drug abuse,~* Prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate,~* Human immunodeficiency virus (HIV) positive,~* Any known condition or circumstance that would prevent, in the investigator's opinion, compliance or completion of the study.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Teriflunomide 7 mg / 14 mg (Type: EXPERIMENTAL): Core treatment period: Teriflunomide 7 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
- Teriflunomide 14 mg / 14 mg (Type: EXPERIMENTAL): Core treatment period: Teriflunomide 14 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
- Placebo / Teriflunomide 14 mg (Type: PLACEBO_COMPARATOR): Core treatment period: Placebo (for teriflunomide) once daily. Extension treatment period: Teriflunomide 14 mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).